General Nurse Practitioner News

NP

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cady R et al. – Providing a greater quantity of 10 mg rizatriptan orally disintegrating tablet (ODT) did not reduce the number of migraine days compared with providing 9 tablets per month for this population with episodic migraine with a frequency of 3–8 migraines per month. Regardless of quantity provided, rizatriptan was generally well tolerated.

Related Articles

Topiramate in migraine progression
The Journal of Headache and Pain, 10/21/09    Relevance Score: 69%

CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine
Expert Review of Neurotherapeutics, 11/12/09    Relevance Score: 68%

Controversies in migraine
Nurse Prescribing, 10/09/09    Relevance Score: 68%

Ankle-Brachial Index, a Screening for Peripheral Obstructive Arterial Disease, and Migraine – A Controlled Study
Headache: The Journal of Head and Face Pain, 10/07/09    Relevance Score: 68%

New drugs for migraine
The Journal of Headache and Pain, 10/05/09    Relevance Score: 68%

Today in Clinical Pharmacology...keeping you current

Interferon-gamma (INF-gamma) release test can detect cutaneous adverse effects to statins
International Journal of Dermatology, 12/03/09

Amlodipine/Valsartan/Hydrochlorothiazide: Fixed-Dose Combination in Hypertension
American Journal of Cardiovascular Drugs, 12/03/09

Beta-Blocker Therapy and Mortality of Patients with Chagas' Cardiomyopathy—a subanalysis of the REMADHE prospective trial
Circulation: Heart Failure, 12/03/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address